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Abstract
A number of open questions in human evolutionary genetics would become tractable if we
were able to directly measure evolutionary fitness. As a step towards this goal, we devel-
oped a method to examine whether individual genetic variants, or sets of genetic variants,
currently influence viability. The approach consists in testing whether the frequency of an
allele varies across ages, accounting for variation in ancestry. We applied it to the Genetic
Epidemiology Research on Adult Health and Aging (GERA) cohort and to the parents of par-
ticipants in the UK Biobank. Across the genome, we found only a few common variants with
large effects on age-specific mortality: tagging the APOE ε4 allele and near CHRNA3.
These results suggest that when large, even late-onset effects are kept at low frequency by
purifying selection. Testing viability effects of sets of genetic variants that jointly influence 1
of 42 traits, we detected a number of strong signals. In participants of the UK Biobank of Brit-
ish ancestry, we found that variants that delay puberty timing are associated with a longer
parental life span (P~6.2 × 10−6 for fathers and P~2.0 × 10−3 for mothers), consistent with
epidemiological studies. Similarly, variants associated with later age at first birth are associ-
ated with a longer maternal life span (P~1.4 × 10−3). Signals are also observed for variants
influencing cholesterol levels, risk of coronary artery disease (CAD), body mass index, as
well as risk of asthma. These signals exhibit consistent effects in the GERA cohort and
among participants of the UK Biobank of non-British ancestry. We also found marked differ-
ences between males and females, most notably at the CHRNA3 locus, and variants associ-
ated with risk of CAD and cholesterol levels. Beyond our findings, the analysis serves as a
proof of principle for how upcoming biomedical data sets can be used to learn about selec-
tion effects in contemporary humans.
Author summary
Our global understanding of adaptation in humans is limited to indirect statistical infer-
ences from patterns of genetic variation, which are sensitive to past selection pressures.
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We introduced a method that allowed us to directly observe ongoing selection in humans
by identifying genetic variants that affect survival to a given age (i.e., viability selection).
We applied our approach to the GERA cohort and parents of the UK Biobank partici-
pants. We found viability effects of variants near the APOE and CHRNA3 genes, which are
associated with the risk of Alzheimer disease and smoking behavior, respectively. We also
tested for the joint effect of sets of genetic variants that influence quantitative traits. We
uncovered an association between longer life span and genetic variants that delay puberty
timing and age at first birth. We also detected detrimental effects of higher genetically pre-
dicted cholesterol levels, body mass index, risk of coronary artery disease (CAD), and risk
of asthma on survival. Some of the observed effects differ between males and females,
most notably those at the CHRNA3 gene and variants associated with risk of CAD and
cholesterol levels. Beyond this application, our analysis shows how large biomedical data
sets can be used to study natural selection in humans.
Introduction
A number of central questions in evolutionary genetics remain open, in particular for humans.
Which types of variants affect fitness? Which components of fitness do they affect? What is the
relative importance of directional and balancing selection in shaping genetic variation? Part of
the difficulty is that our understanding of selection pressures acting on the human genome is
based either on experiments in fairly distantly related species or cell lines or on indirect statisti-
cal inferences from patterns of genetic variation [1–3].
The statistical inferences rely on patterns of genetic variation in present-day samples (or,
very recently, in ancient samples [4]) to identify regions of the genome that appear to carry
the footprint of positive selection [2]. For example, a commonly used class of methods asks
whether rates of nonsynonymous substitutions between humans and other species are higher
than expected from putatively neutral sites in order to detect recurrent changes to the same
protein [5]. Another class instead relies on polymorphism data and looks for various footprints
of adaptation involving single changes of large effect [6]. These approaches detect adaptation
over different timescales and, likely as a result, suggest quite distinct pictures of human adapta-
tion [1]. For example, approaches that are sensitive to selective pressures acting over millions
of years have identified individual chemosensory and immune-related genes (e.g., [7]). In con-
trast, approaches that are most sensitive to selective pressures active over thousands or tens of
thousands of years have revealed strong selective pressures on individual genes that influence
human pigmentation (e.g., [8–10]), diet [11–13], as well as sets of variants that shape height
[14–16]. Even more recent still, studies of contemporary populations have suggested that natu-
ral selection has influenced life-history traits like age at first childbirth as well as educational
attainment over the course of the last century [17–23].
Because these approaches are designed (either explicitly or implicitly) to be sensitive to a
particular mode of adaptation, they provide a partial and potentially biased picture of what
variants in the genome are under selection. In particular, most have much higher power to
adaptations that involve strongly beneficial alleles that were rare in the population when first
favored and will tend to miss selection on standing variation or adaptation involving many
loci with small beneficial effects (e.g., [24–27]). Moreover, even where these methods identify a
beneficial allele, they are not informative about the components of fitness that are affected or
about possible fitness trade-offs between sexes or across ages.
Viability selection in contemporary humans
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In line with Lewontin’s proposal to track age-specific mortality and fertility of hundreds of
thousands of individuals [28], we sought a more direct and, in principle, comprehensive way
to study adaptation in humans, focusing on current viability selection. Similar to the approach
that Allison took in comparing frequencies of the sickle cell allele in newborns and adults liv-
ing in malarial environments [29], we aimed to directly observe the effects of genotypes on
survival by taking advantage of the recent availability of genotypes from large cohorts of indi-
viduals of different ages. Specifically, we tested for differences in the frequency of an allele
across individuals of different ages, controlling for changes in ancestry and possible batch
effects. This approach resembles a genome-wide association study (GWAS) for longevity yet
does not focus on an end point (e.g., survival to an old age) but on any shift in allele frequen-
cies with age. Thus, it allows the identification of possible nonmonotonic effects at different
ages or sex differences. Any genetic variant that affects survival by definition has a fitness cost,
even if the cost is too small to be effectively selected against (depending on the effective popula-
tion size, the age structure of the population, and the age at which the variant exerts its effects
[30]). Of course, a genetic variant can influence fitness without influencing survival through
effects on reproduction or inclusive fitness. Our approach is therefore considering only 1 of
the components of fitness that are likely important for human adaptation.
As a proof of principle, we applied our approach to 2 recent data sets: to 57,696 individuals
of European ancestry from the Genetic Epidemiology Research on Adult Health and Aging
(GERA) cohort [31,32] and, by proxy [33–35], to the parents of 117,648 individuals of British
ancestry surveyed as part of the UK Biobank [36]. We did so for individual genetic variants
then jointly for sets of variants previously found to influence 1 of 42 polygenic traits [37–40].
Results
A method for testing for differences in allele frequencies across age bins
If a genetic variant does not influence viability, its frequency should be the same in individuals
of all ages. We therefore tested for changes in allele frequency across individuals of different
ages, while accounting for systematic differences in the ancestry of individuals of different ages
(for example, due to migration patterns over decades) and genotyping batch effects. We used a
logistic regression model in which we regressed each individual’s genotype on their age bin,
their ancestry as determined by principal component analysis (PCA) (S1 Fig), and the batch in
which they were genotyped (see Materials and methods for details). In this model, we treated
age bin as a categorical variable; this approach allowed us to test for a relationship between age
and the frequency of an allele regardless of the functional form of this relationship. We also
tested a model with an interaction between age and sex to assess whether a variant affects sur-
vival differently in the 2 sexes.
We first evaluated the power of this method using simulations. We considered 3 possible
trends in allele frequency with age: (i) a constant frequency up to a given age followed by a
steady decrease, i.e., a variant that affects survival after a given age (e.g., variants contributing
to late-onset disorders), (ii) a steady decrease across all ages for a variant with detrimental
effect throughout life, and (iii) a U-shaped pattern in which the allele frequency decreases to a
given age but then increases, reflecting trade-offs in the effects at young and old ages, as
hypothesized by the antagonistic pleiotropy theory of aging [41] or as may be seen if there are
protective alleles that buffer the effect of risk alleles late in life [42] (Fig 1). In all simulations,
we used sample sizes and age distributions that matched the GERA cohort (S2 Fig). For sim-
plicity, we also assumed no population structure or batch effects across age bins (see Materials
and methods). For all trends, we set a maximum of 20% change in the allele frequency from
the value in the first age bin (Fig 1).
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Because of the age distribution of individuals in the GERA cohort (S2 Fig), our power to
detect the trend is greater when most of the change in allele frequency occurs in middle age
(Fig 1). For example, for an allele with an initial allele frequency of 0.15 that begins to decrease
in frequency among individuals at age 20, age 50, or age 70 years, there is around 20%, 90%,
and 60% power, respectively, to detect the trend at P< 5 × 10−8, the commonly used criterion
for genome-wide significance [44]. We also experimented with a version of the model in
which the age bin is treated as an ordinal variable; as expected, this model is more powerful if
there is in fact a linear relationship between age and allele frequency. Because we do not know
the functional form of the relationship between age and allele frequency a priori in most cases,
we used the categorical model for all analyses unless otherwise noted.
Fig 1. Power of the model to detect changes in allele frequency with age. (A) Trends in allele frequency with age
considered in simulations. The y-axis indicates the allele frequency standardized to the frequency in the first age bin. (B)
Power to detect the trends in (A) at P < 5 × 10−8, given the sample size per age bin in the Genetic Epidemiology Research on
Adult Health and Aging (GERA) cohort (S2 Fig and total sample size of 57,696). Shown are results using models with age
treated as a categorical (red) or an ordinal (black) variable, assuming no change in population structure and batch effects
across age bins. The curves show simulation results sweeping allele frequency values with an increment value of 0.001 (1,000
simulations for each allele frequency) smoothed using a Savitzky-Golay filter in the SciPy package [43].
https://doi.org/10.1371/journal.pbio.2002458.g001
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In the UK Biobank, all individuals were 45–69 years old at enrollment, so the age range
of the participants is restricted and our method has low power. However, the UK Biobank
participants reported the survival status of their parents: age of the parents if alive or age at
which their parents died; following recent studies [33–35], we therefore used these values
(when reported) instead in our model. In this situation, we are testing for correlations between
an allele frequency and father’s or mother’s age (if alive) or age at death (if deceased). This
approach obviously comes with the caveat that children inherit only half of their genome from
each parent and so power is reduced (e.g., [45]). Furthermore, the patterns expected when
considering individuals who have died differ subtly from those generated among surviving
individuals. Notably, when an allele begins to decline in frequency starting at a given age (Fig
1A), there should be an increase in the allele frequency among individuals who died at that
age followed by a decline in frequency, rather than the steady decrease expected among sur-
viving individuals (S3 Fig, see Materials and methods for details). In a first analysis, we there-
fore focused on the majority of participants who reported father’s or mother’s age at death,
88,595 and 71,783 individuals, respectively. We compared the results of this approach with the
results of a Cox proportional hazards model [46], which allowed us to include individuals who
reported their parents to be alive but has the disadvantage of assuming fixed effects across all
ages.
We further adapted this model to allow us to test for changes in frequency at sets of genetic
variants jointly. Many phenotypes of interest, from complex disease risk to anthropomorphic
and life-history traits such as age at menarche, are polygenic [47,48]. If a polygenic trait has an
effect on fitness, either directly or indirectly (i.e., through pleiotropic effects), the individual
loci that influence the trait may be too subtle in their survival effects to be detectable with cur-
rent sample sizes. We therefore investigated whether there is a shift across ages in sets of
genetic variants that were identified as influencing a trait in GWASs (S1 Table). Specifically,
for a given trait, we calculated a polygenic score for each individual based on trait effect sizes
of single variants previously estimated in GWASs and then tested whether the scores vary sig-
nificantly across 5-year age bins (see Materials and methods for details). These scores are cal-
culated under an additive model, which appears to provide a good fit to GWAS data [49].
If a polygenic trait is under stabilizing selection (e.g., human birth weight [50]), i.e., an
intermediate polygenic score is optimal, no change in the mean value of polygenic scores
across different ages is expected. However, if extreme values of a trait are associated with lower
chance of survival, the spread of the polygenic scores should decrease with age. To consider
this possibility, we tested whether the squared difference of the polygenic scores from the
mean varies significantly with age (see Materials and methods for details).
Testing for changes in allele frequency at individual genetic variants
We first applied the method to the GERA cohort using 8,868,517 filtered genotyped and
imputed autosomal biallelic single-nucleotide polymorphisms (SNPs) and indels. We focused
on a subset of 57,696 filtered individuals who we confirmed to be of European ancestry by
PCA (see Materials and methods, S4 and S5 Figs). The ages of these individuals were reported
in bins of 5-year intervals (distribution shown in S2 Fig). We tested for significant changes in
allele frequencies across these bins. For each variant, we obtained a P value comparing a model
in which the allele frequency changes with age to a null model. No inflation was detected in
the quantile-quantile plot (S6A Fig), indicating that, for common variants at least, our control
for population structure (and other potential confounders) is sufficient. To illustrate this
point, we looked at the lactose intolerance-linked SNP rs4988235 within the LCT locus, which
is among the most differentiated variants across European populations [11]; the trend in the
Viability selection in contemporary humans
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expected allele frequency based on the null model (i.e., accounting for confounding batch
effects and changes in ancestry) tracks the observed trend quite well (S7 Fig).
By our approach, all variants that reached genome-wide significance (P< 5 × 10−8) reside
on chromosome 19 near the APOE gene (Fig 2A and S8 Fig). This locus has previously been
associated with longevity in multiple studies [51,52]. The APOE ε4 allele is known to increase
the risk of late-onset Alzheimer disease (AD) as well as of cardiovascular diseases [53,54]. We
observe a monotonic decrease in the frequency of the T allele of the ε4 tag SNP rs6857 (C, pro-
tective allele; T, risk allele) beyond the age of 70 years old (Fig 2B). This trend is observed for
both the heterozygous and homozygous risk variants (S9 Fig) and for both males and females
(S10 Fig). No variant reaches genome-wide significance testing for age by sex interactions
(quantile-quantile plot shown in S6B Fig).
We further investigated the trends in frequency with age for the other 2 major APOE alleles
defined by rs7412 and rs429358 SNPs: ε2 (rs7412-T, rs429358-T) and ε3 (rs7412-C, rs429358-
T), while ε4 is known by rs7412-C and rs429358-C alleles. Unlike the ε4 allele, ε2 allele carriers
are suggested to be at lower risk of AD, cardiovascular disease, and mortality relative to the ε3
carriers [51,55]. We focused on a subset of 38,703 individuals with unambiguous counts of
each APOE allele. There is a significant change in the frequency of the ε4 allele with age in this
subset (P~6.0 × 10−12), similar to the trend observed for the tag SNP rs6857 (S11 Fig). The ε3
allele shows the reverse trend, with a significant, monotonic increase in frequency beyond the
age of 70 years old (P~1.7 × 10−8) (S11 Fig). The enrichment of the ε3 allele in elderly individu-
als can be explained by the corresponding depletion of the ε4 allele and does not necessarily
imply an independent, protective effect of the ε3 allele. The frequency of the ε2 allele does not
change significantly with age (P~0.21), possibly reflecting low power given its allele frequency
of approximately 0.06 (S11 Fig).
Fig 2. Testing for the influence of single genetic variants on age-specific mortality in the Genetic Epidemiology Research
on Adult Health and Aging (GERA) cohort. (A) Manhattan plot of P values for the change in allele frequency with age. The red line
marks the P = 5 × 10−8 threshold. (B) Allele frequency trajectory of rs6857, a tag SNP for the APOE ε4 allele, with age. Data points are
the frequencies of the risk allele within 5-year interval age bins (± 2 SE), with the center of the bin indicated on the x-axis (except for
the first and the last points). Bins with ages below 38 years are merged into 1 bin because of the relatively small sample sizes. The
dashed line shows the expected frequency based on the null model, accounting for confounding batch effects and changes in
ancestry (see Materials and methods). In orange are the mean ages at onset of Alzheimer disease for carriers of 0, 1, or 2 copies of
the APOE ε4 allele [53]. See S1 Data for underlying data.
https://doi.org/10.1371/journal.pbio.2002458.g002
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We considered the possibility that some unobserved confounding variable was driving the
strength of this signal at APOE. Since there are 2 genotyped SNPs with signals similar to
rs6857 within the locus, genotyping error seems unlikely to be driving the pattern (S8 Fig).
Another concern might be a form of ascertainment bias, in which individuals with AD are
underrepresented in the Kaiser Permanente Medical Care Plan. However, there is no correla-
tion in these data between the amount of time that an individual has been enrolled in this plan
and the individual’s APOE genotype (S12 Fig). These observations, along with previously
reported associations at this locus, argue that the allele frequency trends in Fig 2B are driven
by effects of APOE genotype on mortality (or severe disability). Moreover, the effects that we
identified are concordant with epidemiological data on the mean age at onset of AD, given 0 to
2 copies of APOE ε4 allele [53]. This case not only serves as a positive control for our approach,
it illustrates the resolution that it provides about age effects of genetic variants.
We estimated that we have about 93% power to detect the trend in allele frequency with age
as observed for rs6857 (at a genome-wide significance level, see Materials and methods). Using
both versions of the model treating age bin as a categorical or an ordinal variable, we have sim-
ilar power to detect other potential trends considered in Fig 1 for variants as common as
rs6857 and with similar magnitude of effect on survival. Yet across the genome, only APOE
variants show a significant change in allele frequency with age for both versions of the model
(Fig 2 and S13 Fig). Thus, our finding only APOE ε4 allele indicates that there are few or no
other common variants in the genome with an effect on survival as strong as is seen in the
APOE region.
We then turned to the UK Biobank data set. We applied our method to individuals of Brit-
ish ancestry whose data passed our filters; of these, 88,595 had death information available for
their father and 71,783 for their mother. We analyzed 590,437 genotyped autosomal variants,
applying similar quality control (QC) measures as with the GERA data set (see Materials and
methods). We tested for significant changes in allele frequencies with father’s age at death and
mother’s age at death stratified in eight 5-year interval bins. As in the GERA data set, no infla-
tion was detected in the quantile-quantile plots (S14 Fig).
Consistent with recent studies [33,34], the variants showing a genome-wide significant
change in allele frequency with father’s age at death (P< 5 × 10−8) reside within a locus con-
taining the nicotine receptor gene CHRNA3 (Fig 3A). The A allele of the CHRNA3 SNP
rs1051730 (G, major allele; A, minor allele) has been shown to be associated with increased
smoking quantity among individuals who smoke [56]. We observe a linear decrease in the fre-
quency of the A allele of rs1051730 throughout almost all age ranges (Fig 3B) (P~1.3 × 10−7
and P~2.7 × 10−10, treating paternal age at death as a categorical or an ordinal variable, respec-
tively). Although it does not reach genome-wide significance, this allele shows a similar trend
with age in GERA (P~8.6 × 10−3, S15 Fig). We note that 30,819 of the UK Biobank individuals
included in the above analysis were genotyped on the UK BiLEVE Axiom array (see Materials
and methods), selected based on lung function and smoking behavior (while the remaining
57,776 samples were genotyped on the UK Biobank Axiom array) [57]. Expectedly, the fre-
quency of the A allele is significantly higher among UK BiLEVE subjects (P~2.3 × 10−10), but
the age effects are similar across both arrays (P~0.72, see Materials and methods).
For mother’s age at death, a SNP in a locus containing the MEOX2 gene reached genome-
wide significance (Fig 3C). The C allele of rs4721453 (T, major allele; C, minor allele) increases
in frequency in the age bin centered at 76 years old (S16 Fig), i.e., there is an enrichment
among individuals who died at 74 to 78 years of age, which corresponds to a deleterious effect
of the C allele in this period. The trend is similar and nominally significant for other genotyped
common SNPs in moderate linkage disequilibrium with rs4721453 (S16 Fig). Also, the signal
for rs4721453 remains nominally significant when using subsets of individuals genotyped on
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the same genotyping array: 44,552 individuals on the UK Biobank Axiom array (P~6.6 × 10−5)
and 25,231 individuals on the UK BiLEVE Axiom array (P~1.1 × 10−4). These observations
suggest that the result is not due to genotyping errors, but it is not reproduced in GERA
(P~0.023, S17 Fig) and so it remains to be replicated. Variants within the APOE locus are
among the top nominally significant variants (Fig 3C). At the APOE SNP rs769449 (G, major
allele; A, minor allele), there is an increase in the frequency of A allele at around 70 years old
before subsequent decrease (Fig 3D, P~1.2 × 10−7). This pattern is consistent with our finding
in GERA (of a monotonic decrease beyond 70 years of age), considering the difference in
Fig 3. Testing for the influence of single genetic variants on age-specific mortality in the UK Biobank. (A) Manhattan plot of
P values, obtained from testing for a change in allele frequency with age at death of fathers. (B) Allele frequency trajectory of
rs1051730, within the CHRNA3 locus, with father’s age at death. (C) Manhattan plot of P values, obtained from testing for a change
in allele frequency with age at death of mothers. (D) Allele frequency trajectory of rs769449, within the APOE locus, with mother’s
age at death. Red lines in (A) and (C) mark the P = 5 × 10−8 threshold. Data points in (B) and (D) are the frequencies of the risk allele
within 5-year interval age bins (± 2 SE), with the center of the bin indicated on the x-axis (except for the first and the last points). The
dashed line shows the expected frequency based on the null model, accounting for confounding batch effects and changes in
ancestry (see Materials and methods). See S2 Data for underlying data.
https://doi.org/10.1371/journal.pbio.2002458.g003
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patterns expected between allele frequency trends with age among survivors versus individuals
who died (S3 Fig).
We note that by considering parental age at death of the UK Biobank participants—as done
also in [33–35]—we introduce a bias towards older participants, who are more likely to have
deceased parents (S18 Fig). We confirmed that our top signals are not significantly affected
after adjusting for age of the participants (among other potential confounders, including par-
ticipants’ sex, year of birth, and socioeconomic status, as measured by the Townsend depriva-
tion index): results remain similar for the SNP rs4721453 near MEOX2 (P~2.1 × 10−9), APOE
SNP rs769449 (P~1.5 × 10−6), and CHRNA3 SNP rs1051730 (P~1.8 × 10−6 and P~4.3 × 10−9,
treating paternal age at death as a categorical or an ordinal variable, respectively).
We further tested for trends in allele frequency with parental age at death that differ
between fathers and mothers, focusing on 62,719 individuals with age at death information for
both parents. No variant reached genome-wide significance level (S19A Fig). The rs4721453
near the MEOX2 gene and APOE variant rs769449 show nominally significant sex effects
(P~7.2 × 10−8 and P~2.2 × 10−3, respectively), with stronger effects in females (S19B Fig). Vari-
ants near the CHRNA3 locus are nominally significant when using the model with parental
ages at death treated as ordinal variables (rs11858836, P~5.7 × 10−4), with stronger effects in
males (S19B Fig).
Testing for changes in allele frequency at trait-associated variants
We next turned to sets of genetic variants that have been associated with polygenic traits rather
than individual genetic variants. We focused on 42 polygenic traits, including disease risk and
traits of evolutionary importance such as puberty timing, for which a large number of common
variants have been mapped in GWASs (see S1 Table for the list of traits and number of loci)
[37–40]. For each individual and each trait, we calculated a polygenic score based on the genetic
variants that reached genome-wide significance level for association and then tested whether
this polygenic score, or its squared difference from the mean in the case of stabilizing selection,
is associated with survival (after controlling for covariates, see Materials and methods).
We first applied the Cox proportional hazards model in the UK Biobank for parental sur-
vival, focusing on the participants whose genetic ancestry is British and who reported their
father’s or mother’s age or age at death (114,122 and 116,323 individuals, respectively). We
then compared the results with our approach of testing for changes in the polygenic score
across parental ages at death. We further analyzed 2 data sets for replication purposes: partici-
pants of the UK Biobank of non-British ancestry (29,511 and 30,372 individuals reporting
father’s or mother’s age information, respectively) and the GERA cohort.
Using the Cox model, the scores for several traits show significant associations with father’s
survival after accounting for multiple testing (Fig 4A, Table 1): total cholesterol (TC,
P~4.3 × 10−11), low-density lipoproteins (LDL, P~8.1 × 10−9), body mass index (BMI,
P~1.8 × 10−8), and coronary artery disease (CAD, P~9.0 × 10−6), consistent with 2 recent stud-
ies [34,35]. In addition, we uncovered significant association for the polygenic score for
puberty timing (P~6.2 × 10−6); in this analysis, we used age at menarche-associated variants in
females, motivated by the high genetic correlation between the timing of puberty in males and
females [58]). A higher score for puberty timing is associated with longer paternal survival
(per year hazard ratio of 0.96) (Table 1), indicating that variants delaying puberty timing are
associated with a higher chance of survival, consistent with epidemiological studies suggesting
early puberty timing to be associated with adverse health outcomes [59]. For all other traits, a
higher score is negatively associated with paternal survival: 1 unit polygenic score hazard ratio
of 1.09 for TC, 1.08 for LDL, 1.08 for CAD, and 1.22 for BMI (Table 1). With the exception of
Viability selection in contemporary humans
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Fig 4. Testing for the influence of sets of trait-associated variants on survival of the fathers of UK Biobank participants. (A)
Quantile-quantile plot for association between the polygenic score of 42 traits (see S1 Table) with father’s survival, using the Cox
model. The red line indicates the distribution of the P values under the null model. Signs “+” and “−” indicate protective and detrimental
effects associated with higher values of polygenic scores, respectively. See S2 Table for P values and hazard ratios for all traits. (B–F)
Trajectory of polygenic score with age at death of fathers for top traits associated with paternal survival (only independent signals are
shown, see S20 Fig): puberty timing (using age at menarche-associated variants) in males (B), total cholesterol (TC) (C), coronary
artery disease (CAD) (D), body mass index (BMI) (E), and asthma (ATH) (F). Data points in (B–F) are mean polygenic scores within
5-year interval age bins (± 2 SE), with the center of the bin indicated on the x-axis (except for the first and the last points). The dashed
line shows the expected score based on the null model, accounting for confounding batch effects, changes in ancestry, and
participant’s age, sex, year of birth, and the Townsend index (a measure of socioeconomic status). See S2 Data for underlying data.
https://doi.org/10.1371/journal.pbio.2002458.g004
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lipid traits, the effects on survival are not significantly changed after accounting for the effect
of the polygenic score of another trait (S20 Fig). This is especially relevant to BMI and puberty
timing, for which there is substantial genetic overlap [38]; the per year hazard ratio is 0.97 for
the puberty timing score (P~4.8 × 10−4) after adjusting for the BMI score.
Using our approach instead, i.e., considering the father’s age at death, led to very similar
results. Specifically, all traits significantly associated with paternal survival show a significant
change in polygenic score with father’s age at death using the model with parental ages at
death treated as ordinal variables (S21 Fig): TC (P~8.8 × 10−9), CAD (P~3.3 × 10−8), puberty
timing (P~1.6 × 10−7), LDL (P~8.6 × 10−7), and BMI (P~3.4 × 10−6). In addition, we uncovered
significant changes in polygenic score with father’s age at death for asthma (ATH, P~9.4 ×
10−5) and triglycerides (TG, P~4.4 × 10−4, the effect of which does not seem to be distinct from
other lipid traits, S20 Fig). The score for puberty timing increases monotonically with the
father’s age at death (Fig 4B), indicative of a protective effect of later predicted puberty timing,
whereas all other traits with significant signal show a monotonic decline in score with age (Fig
4C–4F).
In a Cox survival model, for mothers as with for fathers, scores for TC, CAD, and LDL are
significantly associated with survival, with similar hazard ratios (Fig 5A and Table 1): 1 unit
polygenic score hazard ratio of 1.09 for LDL (P~5.2 × 10−8), 1.09 for CAD (P~5.2 × 10−6), and
1.07 for TC (P~7.8 × 10−6). In addition, the high-density lipoproteins (HDL) score is associ-
ated with maternal survival (1 standard deviation (SD) hazard ratio of 0.94, P~8.9 × 10−5).
Also, suggestive evidence was detected for protective effects of increased predicted age at first
birth (AFB) (per year hazard ratio of 0.94, P~1.4 × 10−3) as well as predicted puberty timing
(per year hazard ratio of 0.97, P~2.0 × 10−3) (Fig 5A and Table 1). Other than the LDL and TC,
all signals seem to be distinct (S20 Fig), including for puberty timing and AFB, despite the
genetic correlation between the 2 phenotypes [39].
In turn, applying our approach to maternal age at death, puberty timing and AFB are the
top signals (P~2.2 × 10−4 and P~3.1 × 10−3, respectively, S21 Fig). Higher polygenic scores for
puberty timing are enriched among longer-lived mothers (Fig 5B), as seen for fathers. Simi-
larly, the score for AFB increases with mother’s age at death (Fig 5C), indicating an association
between variants that delay AFB and longer life span. Scores for CAD, LDL, and HDL did not
show significant monotonic change across mother’s age at death bins (P~7.7 × 10−3, P~0.058,
and P~0.35, respectively); however, the trends are suggestive of subtle age-dependent effects,
Table 1. Associations between sets of trait-associated variants and paternal and maternal survival among the UK Biobank participants of British
ancestry, under the Cox model.
Trait Scaling of effect Father Mother
Effect size (SE) HR P value Effect size (SE) HR P value
Puberty timing 1 year −0.0363 (0.0080) 0.96 6.2 × 10−6 −0.0278 (0.0090) 0.97 0.0020
AFB 1 year −0.0398 (0.0180) 0.96 0.027 −0.0639 (0.0200) 0.94 0.0014
ATH 1 unit log-odds 0.0279 (0.0109) 1.03 0.010 0.0149 (0.0121) 1.02 0.22
BMI 1 SD 0.1996 (0.0355) 1.22 1.8 × 10−8 0.0823 (0.0395) 1.08 0.037
CAD 1 unit log-odds 0.0784 (0.0177) 1.08 9.0 × 10−6 0.0892 (0.0196) 1.09 5.2 × 10−6
HDL 1 SD −0.0340 (0.0139) 0.97 0.014 −0.0605 (0.0154) 0.94 8.9 × 10−5
LDL 1 SD 0.0806 (0.0140) 1.08 8.1 × 10−9 0.0844 (0.0155) 1.09 5.2 × 10−8
TC 1 SD 0.0901 (0.0137) 1.09 4.3 × 10−11 0.0679 (0.0152) 1.07 7.8 × 10−6
Abbreviations: AFB, age at first birth; ATH, asthma; BMI, body mass index; CAD, coronary artery disease; HR, hazard ratio; HDL, high-density
lipoproteins; LDL, low-density lipoproteins; TC, total cholesterol
https://doi.org/10.1371/journal.pbio.2002458.t001
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Fig 5. Testing for the influence of sets of trait-associated variants on survival of the mothers of UK Biobank participants.
(A) Quantile-quantile plot for association between the polygenic score of 42 traits (see S1 Table) with mother’s survival, using the
Cox model. The red line indicates the distribution of the P values under the null. Signs “+” and “−” indicate protective and detrimental
effects associated with higher values of polygenic scores, respectively. See S2 Table for P values and hazard ratios for all traits. (B–
F) Trajectory of polygenic score with age at death of mothers for top traits associated with maternal survival (only independent
signals are shown, see S20 Fig): puberty timing (B), age at first birth (AFB) (C), coronary artery disease (CAD) (D), low-density
lipoproteins (LDL) (E), and high-density lipoproteins (HDL) (F). Data points in (B–F) are mean polygenic scores within 5-year interval
age bins (± 2 SE), with the center of the bin indicated on the x-axis (except for the first and the last points). The dashed line shows the
expected score based on the null model, accounting for confounding batch effects, changes in ancestry, and participant’s age, sex,
year of birth, and the Townsend index (a measure of socioeconomic status). See S2 Data for underlying data.
https://doi.org/10.1371/journal.pbio.2002458.g005
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with an effect of CAD score in middle age and late-onset effects of LDL and HDL scores (Fig
5D–5F). Testing for age by sex interactions, the TC and CAD score trends with parental ages
at death are significantly different between fathers and mothers (P~4.0 × 10−4 and
P~7.4 × 10−4, respectively, S22 Fig).
To further investigate the age dependency of the effects, we plotted polygenic scores among
parents who had survived up to a given age as compared to the trends with parental ages at
death (S23 and S24 Figs). All traits associated with paternal survival seemingly show more pro-
nounced effects in middle age (S23 Fig). Similar patterns were observed for maternal survival-
associated traits except for LDL and HDL, which had more pronounced late-age effects (S24
Fig). We also compared the hazard ratios for ages at death of 75 and> 75 years (Materials
and methods), similar to a recent study [33]. Consistent with trends in scores with parental
age, among the traits associated with paternal survival, almost all traits have seemingly stronger
effects among younger fathers, particularly for CAD (S3 Table): 1 unit log-odds hazard ratio of
1.14 for younger fathers (P~2.6 × 10−9) and 0.99 for older fathers (P~0.70). Unlike in fathers,
in mothers, TC, LDL, and HDL scores had more pronounced late-age effects (S3 Table):
for TC, 1 SD hazard ratio of 1.03 for younger mothers (P~0.15) and 1.11 for older mothers
(P~1.4 × 10−6) and for LDL, 1 SD hazard ratio of 1.05 for younger mothers (P~0.03) and 1.12
for older mothers (P~3.3 × 10−8).
Next, we sought to replicate the top associations observed among the UK Biobank partici-
pants of British ancestry (discovery cohort) in 2 other data sets: participants of the UK Biobank
of non-British ancestry and the GERA cohort. Applying the Cox model using parental survival
for UK Biobank participants of non-British ancestry, the direction of hazard ratios for all traits
(as well as the estimated values for most traits) are consistent with the discovery cohort for
both fathers and mothers (S4 Table). The congruence of results in 2 cohorts with different
ancestries suggests that our top signals are not false positives caused by poor control for popu-
lation structure. In the GERA cohort, we tested whether polygenic scores change with the age
of the participant, similar to our approach for individual genetic variants in this cohort. All top
signals except AFB have directionally consistent effects with the discovery cohort (S5 Table).
Of particular interest, the strongest signal is an increase in the polygenic score for puberty tim-
ing with age of the participants (P~6.7 × 10−3, S25 Fig).
In the discovery cohort, we further investigated if there are significant changes in the
squared difference of polygenic scores with parental ages at death, as might be expected if the
mean value of the trait leads to the highest chance of survival. No trait shows evidence of such
stabilizing selection (S26 Fig).
Discussion
We introduced a new approach to identify genetic variants that affect survival to a given age
and thus to directly observe viability selection ongoing in humans. Attractive features of the
approach include that we do not need to make a decision a priori about which loci or traits
matter to viability and focus not on an end point (e.g., survival to an old age) but on any shift
in allele frequencies with age, thereby learning about the ages at which effects are manifest and
possible differences between sexes.
To illustrate the potential of our approach, we performed a scan for genetic variants that
impact age-specific mortality in the GERA and the UK Biobank cohorts. We only found a few
individual genetic variants, almost all of which were identified in previous studies. This result
is in some ways expected: available data only provide high power to detect effects of common
variants (>0.15–0.2) on survival (Fig 1), yet if these variants were under viability selection, we
would not expect them to be common, short of strong balancing selection due to trade-offs
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between sexes, ages, or environments. As sample sizes increase, however, the approach intro-
duced here should provide a comprehensive picture of viability selection in humans. To illus-
trate this point, we repeated our power simulation with 500,000 samples and found that we
should have high power to detect the trends for alleles at a couple percent frequency in the
sample (S27 Fig).
Already, however, this application raises a number of interesting questions about the nature
of viability selection in humans. Notably, we discovered only a few individual variants influ-
encing viability in the 2 cohorts, most of which exert their effect late in life. On first thought,
this finding may suggest such variants to be neutrally evolving. We would argue that if any-
thing, our findings of only a few common variants with large effects on survival late in life sug-
gest the opposite: that even variants with late-onset effects have been weeded out by purifying
selection. Indeed, unless the number of loci in the genome that could give rise to such variants
(i.e., the mutational target size) is tiny, other variants such as the APOE ε4 allele must often
arise. That they are not observed when we have very high power to detect them suggests they
are kept at lower frequency by purifying selection. Why might they be selected despite affecting
survival only at old ages? Possible explanations include that they decrease the direct fitness of
males sufficiently to be effectively selected (notably given the large, recent effective population
size of humans [60]) or that they impact the inclusive fitness of males or females. If this expla-
nation is correct, it raises the question of why the APOE ε4 allele has not been weeded out. We
speculate that the environment has changed recently, making this allele more deleterious. For
example, it has been proposed that the evolution of this allele has been influenced by changes
in physical activity [61] and parasite burden [62].
Considering 42 traits that have been investigated by GWASs, we found a number of cases
in which the mean polygenic score changes with age. Of course, detecting an effect of age on
the traits does not imply that these are the phenotypes under viability selection, as the variants
that contribute likely have pleiotropic effects on other traits [37]. Nonetheless, it is perhaps not
surprising that we found detrimental effects of higher genetically predicted TC, LDL, BMI,
and risk of CAD on survival, as these phenotypes are studied in GWASs precisely because of
their adverse health effects. Intriguingly, however, we also found associations for fertility traits,
notably, protective effects of later predicted puberty timing and AFB. If these findings reflect
life-history trade-offs (e.g., longer life span at the cost of delayed reproduction), they may help
to explain the persistence of extensive variation in such fitness-correlated traits [63,64].
Intriguingly, we saw a negative correlation between genetically predicted AFB and number of
siblings of the UK Biobank participants, a proxy for the fertility of their parents (P~4.2 × 10−8,
S28 Fig), consistent with previous reports of a genetic correlation between AFB and the num-
ber of children ever born [21,39]. These findings underscore that consideration of survival or
fertility effects alone does not allow one to infer whether the net effect of a variant or set of var-
iants is beneficial. Instead, to convert effects on viability such as those detected here or effects
on fertility reported elsewhere [22,23] into an understanding of how natural selection acts on
an allele requires a characterization of its effects on all components of fitness (including poten-
tially inclusive fitness).
In this regard, it is also worth noting that while our method is designed to detect changes in
allele frequencies (and in polygenic scores) caused by genetic effects on age-specific mortality,
such changes could in principle also arise from effects on other components of fitness. For
example, if the frequency of a genetic variant in a population decreases over decades due to an
effect on fertility, its frequency would increase with the age of surviving individuals sampled at
a given time (as in the GERA cohort). This confounding is less of an issue when considering
effects on the age at death (what we measured in the UK Biobank). Nonetheless, even in the
UK Biobank, fertility effects may manifest as effects on age at death; for example, when
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sampling a cohort of children, parents with later ages at death are possibly born earlier (S29
Fig). To this end, in the UK Biobank, we accounted for changes in allele frequencies with year
of birth of the participants themselves (ideally, we would want to condition on parents born at
similar times, which we cannot do; instead, we used year of birth of the participants as an esti-
mator for year of birth of the parents). Thus, we believe our results in the UK Biobank not to
be confounded by fertility effects. Moreover, a number of our findings in this study are consis-
tent with prior knowledge of effects on survival, such as those for disease risk variants like the
APOE ε4 allele. Nonetheless, some caution is required in interpreting trends with age as strictly
reflecting viability effects.
Also of interest are the marked differences between males and females in our analysis of
mothers and fathers of individuals in the UK Biobank. The differences between sexes are most
notable at the CHRNA3 locus, which shows a strong effect only in fathers, and sets of genetic
variants associated with risk of CAD and cholesterol levels, which exhibit different age-depen-
dent effects between fathers and mothers. Results for the CHRNA3 locus, in which variants are
associated with the amount of smoking among smokers, may reflect a gene-by-environment
interaction rather than a sex effect per se. Consistent with a more pronounced effect on male
than female age at death, smoking prevalence in men has been consistently higher than
women over the past few decades in the United Kingdom: from 1970 to 2000, smoking preva-
lence decreased from around 70% to 36% in middle-aged men, compared to from around 50%
to 28% in middle-aged women [65].
Moving forward, the application of approaches such as ours to the millions of samples in
the pipeline (such as the UK Biobank [66], the Precision Medicine Initiative program [67], and
the BioVU biobank at Vanderbilt University [68]) will allow viability effects of rare as well as
common alleles to be examined. These analyses will provide a comprehensive answer to the
question of which loci affect survival, helping to address long-standing open questions such as
the relative importance of viability selection in shaping genetic variation and the extent to
which genetic variation is maintained by fitness trade-offs between sexes or across ages.
Materials and methods
Ethics statement
This study used data sets from the UK Biobank (application number 11138), as approved by
the UK Biobank Board, and the Genetic Epidemiology Research on Adult Health and Aging
(GERA), obtained through dbGaP (request numbers 28113–4 and 57119–2) and approved by
Columbia University Institutional Review Board, protocols AAAQ2700 and AAAN4411.
Data sets
GERA cohort. We performed our analyses on the data for 62,318 participants of the
GERA cohort (who are members of the Kaiser Permanente Medical Care Plan, Northern Cali-
fornia Region and participating in its Research Program on Genes, Environment, and Health),
self-reported to be “White-European American”, “South Asian”, “Middle-Eastern”, or “Ashke-
nazi” but no other ethnicities among a list of 23 choices on the GERA survey, and genotyped
on a custom array at 670,176 SNPs designed for Non-Hispanic white individuals [31,32]. We
considered the age of the participants and the number of years they were enrolled in the Kaiser
Permanente Medical Care Plan at the time of the survey (year 2007).
UK Biobank. We performed our analyses on the data for 152,729 participants of the UK
Biobank study, focusing on 120,286 individuals identified to be “British” by genetic analysis,
and all other individuals for replication. They were genotyped on the UK Biobank Axiom or
the UK BiLEVE Axiom SNP arrays at a total of 847,441 SNPs in the interim release [57,66].
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QC
GERA cohort. We used PLINK v1.9 [69] to remove individuals with missing sex informa-
tion or with a mismatch between genotype data and sex information, individuals with<96%
call rate, and individuals with at least one parent in the sample. We validated self-reported
European ancestries using PCA, see below, and removed individuals identified as non-Euro-
pean (S4 and S5 Figs). In the end, 57,696 individuals remained.
Using PLINK, we removed SNPs with<1% minor allele frequency, SNPs with<95% call
rate, and SNPs failing a Hardy-Weinberg equilibrium test with P< 10−8 (filtering based on
HWE test could potentially exclude true signals of viability selection if selection coefficients
were very large [70], but this possibility is much less likely than genotyping error). We addi-
tionally tested for a correlation between age (or sex) and proportion of missing data, which
can induce artificial change in the allele frequencies as a function of age (or sex). We thus
removed SNPs showing a significant age-missingness or sex-missingness correlation, defined
as a chi-squared test with P< 10−7. After these steps, 583,357 SNPs remained.
We imputed the genotypes of the filtered GERA individuals using post-QC SNPs and using
the 1000 Genomes phase 3 haplotypes as a reference panel [71]. We phased observed geno-
types using EAGLE v1.0 software [72]. The inferred haplotypes were then passed to IMPUTE2
v2.3.2 software for imputation in chunks of 1 Mb using the default parameters of the software
[73]. To gain computational speed, variants with minor allele frequency of<0.005 in the 1000
Genomes European populations were removed from the reference panel. This step should not
affect our analysis because our statistical model is not well powered for rare variants, given the
GERA data sample size. We called imputed genotypes with posterior probability of>0.9 and
then filtered the imputed genotypes, removing variants with IMPUTE2 info score of<0.5 and
with minor allele frequency of<0.01. We also used imputation with a leave-one-out approach
[74] to impose a second stage of QC on genotyped SNPs, removing SNPs that were imputed
back with high reported certainty (info score >0.5) and with<90% concordance between the
imputed and the original genotypes. These yielded a total of 8,868,517 imputed and genotyped
biallelic SNPs and indels.
For our analysis of the APOE alleles (ε2, ε3, and ε4), which are defined by rs7412 and
rs429358 SNPs [55], given the lack of tag SNPs for all 3 alleles, we kept a subset of 38,703 indi-
viduals with no poorly imputed genotypes for these 2 SNPs, for whom the count of each APOE
allele could be determined unambiguously.
UK Biobank. In the UK Biobank, we obtained sets of genotype calls and the output of
imputation as performed by the UK Biobank researchers [57,75]. We first applied QC metrics
to the autosomal genotyped SNPs, focusing on the individuals of British genetic ancestry. We
used PLINK to remove SNPs with minor allele frequency of<0.01, SNPs with<95% call rate,
and SNPs failing a Hardy-Weinberg equilibrium test with P< 10−8. These filters were applied
separately to individuals genotyped on the UK Biobank Axiom and the UK BiLEVE Axiom
arrays. Then, we divided the genotyped SNPs into 3 sets (SNPs specific to either array and
shared SNPs) and then performed additional QC on each set separately: we removed SNPs
with significant allele frequency difference between genotyped and imputed calls (chi-squared
test P< 10−5) and SNPs showing a significant correlation between proportion of missing data
and age or sex of the participants as well as with participants’ father’s or mother’s age at death
(chi-squared test P< 10−7). We then extracted this list of SNPs from the imputed genotype
files available from the UK Biobank (we did not use the full set of imputed genotypes). From
this set, we removed SNPs with minor allele frequency of<0.01, SNPs with<95% call rate,
and SNPs failing a Hardy-Weinberg equilibrium test with P< 10−8, yielding 590,437 SNPs.
For variants influencing quantitative traits, we first extracted them from imputed genotype
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files and then imposed similar QC measures as above. For individuals of non-British ancestry,
we first extracted the trait-influencing variants from imputed genotype files and then removed
SNPs with minor allele frequency of<0.01 and SNPs with <90% call rate.
Each participant was asked to provide the survival status and age of their father and their
mother on each assessment visit. For each participant who reported an age at death of father
and/or mother, we averaged over the ages reported at recruitment and any subsequent repeat
assessment visits and used PLINK to exclude individuals with >5-year variation in their
answers across visits (around 800 individuals). For those reporting their parents to be alive, the
latest assessment visit was considered. We also removed adopted individuals, individuals with
a mismatch between genotype data and sex information, and individuals with missing values
for the covariates, resulting in 88,595 individuals of British ancestry with age at death informa-
tion for their father, 71,783 individuals of British ancestry with age at death information for
their mother, and 62,719 individuals of British ancestry with age at death information for both
parents. For the survival analyses, we further removed individuals with evidently invalid
parental survival status, particularly parental ages at death values smaller than their age when
still alive, resulting in 114,122 and 116,323 individuals of British ancestry with paternal and
maternal survival information, respectively. With similar QC measures, 29,511 and 30,372
individuals of non-British ancestry with paternal and maternal survival information, respec-
tively, were analyzed.
PCA
We performed PCA using the EIGENSOFT v6.0.1 package with the fastpca algorithm [76,77]
for 2 purposes: (i) as a QC on individuals to validate self-reported European ancestries (only in
GERA data set) and (ii) to correct for population structure in our statistical model (for individ-
uals in the UK Biobank of non-British ancestry, we used the PCs provided with the data).
European ancestry validation. We used more stringent QC criteria specifically for the
PCA compared to the QC steps described above. We filtered a subset of 157,277 SNPs in
GERA, retaining SNPs shared between the data sets and the 1000 Genomes phase 3 data,
removing nonautosomal SNPs, SNPs with minor allele frequency of<0.01, SNPs with<99%
call rate, and SNPs failing a Hardy-Weinberg equilibrium test with P< 10−6. We then per-
formed LD pruning using PLINK with pairwise r2 < 0.2 in windows of 50 SNPs shifting every
10 SNPs. We used these SNPs to infer principal components for the 1000 Genomes phase 3
data [71]. We then projected individuals onto these PCs. We observed that the majority of
individuals have European ancestry and marked individuals with PCs deviating from the pop-
ulation mean for any of the first 6 PCs as non-European (S4 and S5 Figs).
Control for population structure. After the main QC stage, additional QC steps (as in
European ancestry validation) were implemented for PCA. In the UK Biobank, we also
removed inversion variants on chromosome 8, which otherwise dominate the PC2 (not
shown). A subset of 156,721 SNPs in GERA and 207,657 SNPs in the UK Biobank was then
used to infer PCs for individuals passing QC (S1 Fig). The first 10 PCs were used as covariates
in our statistical model.
Quantitative traits
We downloaded the list of variants contributing to 39 traits (all traits but age at menarche,
AFB, and age at natural menopause) and their effect sizes recently described in Pickrell et al.
[37] from: https://github.com/PickrellLab/gwas-pw-paper/tree/master/all_single. For age at
menarche, we used the variants and effect sizes recently identified by Day et al. [38]. We used
variants associated with AFB from Barban et al. identified in either sex-specific analyses or
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analyses of both sexes and used the effect sizes estimated in the combined analysis [39]. We
used age at natural menopause-associated variants and their effect sizes from Day et al. [40].
For all traits, we used variants that were genotyped/imputed with high quality in our data (see
S1 Table).
Statistical model
An individual variant. Using a logistic regression, we predicted the genotype of individ-
ual j (the counts of an arbitrarily selected reference allele, Gij = 0,1, or 2) at variant i, using the
individual’s ancestry, the batch in which the individual was genotyped, and the individual’s
age (as well as sex, see below) as explanatory variables. Specifically, the distribution of Gij is Bin
(2,pij), where pij, the probability of observing the reference allele for individual j at variant i, is















where βl is the effect of principal component l (to account for population structure), γm is the
effect of being in batch m (to account for potential systematic differences between genotyping
packages), κn is the effect of being in age bin n, obtained by regression across individuals with
nonmissing genotypes at variant i, and I and J are indicator variables for the genotyping batch
and age bin, respectively. In the version of the model in which we treated age as an ordinal var-
iable, we replaced J age bin variables with 1 age variable. In the GERA data set, age binning is
over the age of the participants in 14 categories, from age 19 onwards, in 5-year intervals. For
replication purposes, we further binned the ages in 7 categories, in 10-year intervals, to boost
our power by increasing the sample size per bin, particularly for younger age bins. In the UK
Biobank, we binned the age at death of father or mother over 8 categories, from age 63
onwards, in 5-year intervals. In the UK Biobank, we included all ages at death below 63 in one
age bin to minimize the potential noise caused by accidental deaths at young ages.
We tested for an effect of age categories by a likelihood ratio test with a null model using
only the covariates (PCs and batch terms) (H0: κn = 0, for all n) and an alternative also includ-

































To test for age by sex effects in GERA, we included 2 sets of additional predictors. The first
consists in an indicator variable for sex, K, which is included to capture possible sex effects
induced by potential genotyping errors or mismapping of sex chromosome–linked alleles (we
note that because of Hardy-Weinberg equilibrium, mean allele frequency difference between
males and females is not expected). The second set of predictors consists in age by sex terms,
J × K. We then compared a model with age and sex terms as predictors to a model also includ-
ing age by sex terms. To test for sex effects in the UK Biobank, we compared a model with
both father and mother age terms separately as predictors to a model with 1 set of age catego-
ries for average age at death of both parents, only for individuals reporting the age at death for
both parents. In all models, PCs and batch terms were incorporated as covariates. For the top
SNPs in the UK Biobank, we additionally tested models also including as covariates the
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participants’ age, sex, year of birth, and the Townsend index (a measure of socioeconomic sta-
tus). For rs1051730, we also tested whether allele frequencies or trends in allele frequencies
with the father’s age at death vary significantly across the UK Biobank genotyping arrays after
adjusting for population structures, using similar models as described above.
Set of variants. As for the model described above for an individual variant, we investi-
gated age and age by sex effects on quantitative traits for which a large number of common
genetic variants have been identified in GWASs. For a given trait, we used a linear regression
with the same covariates and predictors as for the model for an individual variant to predict
the polygenic score for individual j, Sj (estimated by summing the previously estimated effects
of single variants, assuming additivity and that the effect sizes are similar in the GWAS panels











Sj is calculated as ∑aiGij + ∑2aiqi (standardized to mean 0), where the first sum is across vari-
ants with nonmissing genotypes, ai is the effect size for the arbitrary selected reference allele at
variant i, and the second sum is across the variants with missing genotypes estimating their
contribution assuming Hardy-Weinberg equilibrium where qi is the frequency of the alternate
allele. Likelihood ratio tests, as described above, were used to test for age and age by sex effects.
In the UK Biobank, we additionally adjusted for participants’ age, sex, year of birth, and the
Townsend index.
To evaluate the possibility of stabilizing selection on a trait, we applied the same model, but
instead of the polygenic score, we regressed the squared difference of the score from the mean
in each bin, ðSj   SBIN;jÞ
2
, on the predictors, where SBIN;j is the mean score in the age bin to
which individual j belongs.
We also used the Cox proportional hazards model [46] to evaluate the association between
polygenic scores and parental survival in the UK Biobank. Compared to the model described
above, this approach presents the advantage of allowing data from participants with alive
parents to be incorporated but has the disadvantage of assuming fixed effects across all ages.
Under this model, at a given time t (age in our application):






gmIj2BATCHm þ k Sj
where λ is the hazard rate (probability of death within t + dt conditional on survival to time t)
given the covariates, and λ0 is the baseline hazard rate that describes the risk for individuals
with the value of 0 for all predictors. Not shown in the equation above are covariates to adjust
for participants’ age, sex, year of birth, and the Townsend index. Using the R package “Sur-
vival” [78], for a given trait, we tested for a significant effect of polygenic score (κ 6¼ 0). In addi-
tion, to assess the interdependence of detected effects (S20 Fig), for each pair of traits [a, b], we
tested for the effect of the polygenic score for trait a but also incorporated the polygenic score
for trait b as a covariate in the null model (in addition to the covariates mentioned above).
We further investigated the age dependency of the effects in the framework of the survival
analysis by comparing hazard ratios in 2 age categories: ages at death of 75 and> 75 years.
For the category of ages at death 75 years, all parental ages were included in the analysis, and
parents with ages at death beyond 75 years were marked as alive. For the category of ages at
death > 75 years, only parents who survived beyond 75 years were considered.
All Manhattan and quantile-quantile plots were generated using qqman [79] and GWAS-
Tools [80] packages.
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Power simulations
We ran simulations to determine the power of our statistical model to detect deviation of allele
frequency trends with age across 14 age categories mimicking the GERA cohort’s age structure
(57,696 individuals with age distribution as in S2 Fig) from a null model, which for simplicity
was no change in frequency with age, i.e., no changes as a result of age-dependent variation in
population structure and batch effects. For a given trend in frequency of an allele with age, we
generated 1,000 simulated trends in which the distribution of the number of the alleles in age
bin i is Bin(2Ni, fi), where Ni and fi are the sample size and the sample allele frequency in bin i.
We then estimated the power to detect the trend as the fraction of cases in which P< 5 × 10−8,
by a chi-squared test.
Survival simulations
We ran simulations to investigate the relationship between allele frequency with age of the sur-
viving individuals and the age of the individuals who died in a cohort. We simulated 2 × 106
individuals going forward in time in 1-year increments. For each time step forward, we tuned
the chance of survival of the individuals based on their count of a risk allele for a given variant
such that the number of individuals dying in the increment complies with: (i) a normal distri-
bution of ages at death with mean of 70 years and standard deviation of 13 years, roughly as is
observed for parental ages at death in the UK Biobank and (ii) a given frequency of the risk
allele among those who survive. Specifically, we modeled the survival rate of the population, S,





where f denotes the frequency of genotypes in the population and x denotes the age. Si and S
are related: Si(x) = S(x) fi(x)/fi, where fi(x) is the genotype frequency among individuals sur-
vived up to age x. Given a trend in allele frequency with age, we calculated genotype frequen-
cies with age assuming Hardy-Weinberg equilibrium and then estimated genotype-dependent
chance of survival, Si(x), taking S(x) as the survival function for N(70, 132).
Supporting information
S1 Fig. Results of principal component analysis (PCA). (A) PCA on 57,696 GERA individu-
als after quality control removing “non-European” individuals. (B) PCA on 120,286 UK Bio-
bank participants of British ancestry. Results are in agreement with recent studies of these data
[77,81].
(TIF)
S2 Fig. Age distribution of the GERA individuals at the time of the survey, year 2007. The
labels on the x-axis indicate the center of 5-year interval age bins (except the last category). See
S1 Data for underlying data.
(TIF)
S3 Fig. Comparison of trends in allele frequency with age and age at death. (A) Simulated
allele frequencies among surviving individuals, reproducing trends as in Fig 1A. (B) Trends in
allele frequency among individuals who died, corresponding to the trends in (A). Points are
allele frequencies within 5-year interval age bins (mean ± 2 SE).
(TIF)
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S4 Fig. Validation of European ancestry in GERA. Shown are PCs inferred for all 26 popula-
tions in the 1000 Genomes Project phase 3 data. For clarity, in each plot, only a few representa-
tive populations are shown. GERA individuals (blue dots) are projected on the inferred PCs.
The dashed lines correspond to the dashed lines in S5 Fig, delimiting the majority of GERA
individuals.
(TIF)
S5 Fig. Distribution of GERA individuals for PCs inferred from 1000 Genome Project
phase 3 data. The dashed lines enclose the majority of the data points; beyond, individuals
were labeled as “non-Europeans.”
(TIF)
S6 Fig. Quantile-quantile plots for model results for individual variants in GERA. Quan-
tile-quantile plots for age (A) and age by sex (B) effects. The red lines indicate the distribution
of the P values under the null model (of no age or age by sex effect) and the shaded bands rep-
resent the 95% confidence intervals, assuming independent SNPs. See S1 Data for underlying
data.
(TIF)
S7 Fig. Frequency of the G allele of rs4988235 with age of the GERA participants. The data
points are the frequencies within 5-year interval age bins (± 2 SE). The x-axis indicates the cen-
ter of the age bin (except for the first and the last bins). Bins with ages below 38 years are
merged into 1 bin because of the relatively small sample sizes per bin. The dashed line shows
the expected frequency based on the null model, accounting for confounding batch effects
and, importantly, changes in ancestry. See S1 Data for underlying data.
(TIF)
S8 Fig. Regional plot for the APOE locus. The y-axis shows P values obtained from a test of
the influence of single genetic variants on age-specific mortality in GERA.
(TIF)
S9 Fig. Frequency of rs6857 genotypes with age in GERA. Frequency of noncarriers (A), het-
erozygous (B), and homozygous (C) carriers of the risk allele for rs6857, tagging the ε4 allele of
the APOE gene, across GERA age bins. Data points are frequencies within 5-year interval age
bins (± 2 SE), with the center of the bin indicated on the x-axis (except for the first and the last
bins). Bins with ages below 38 years are merged into 1 bin because of the relatively small sam-
ple sizes per bin. The dashed line shows the expected frequency based on the null model,
accounting for confounding batch effects and changes in ancestry. See S1 Data for underlying
data.
(TIF)
S10 Fig. Frequency of rs6857 genotypes with age among males and females in GERA. Fre-
quency of noncarriers (A), heterozygous (B), and homozygous (C) carriers of the risk allele for
rs6857, tagging the ε4 allele of the APOE gene, across GERA age bins. Data points are frequen-
cies within 5-year interval age bins (± 2 SE), with the center of the bin indicated on the x-axis
(except for the first and the last bins). Bins with ages below 38 years are merged into 1 bin
because of the relatively small sample sizes per bin. The dashed line shows the expected fre-
quency based on the null model, accounting for confounding batch effects and changes in
ancestry. See S1 Data for underlying data.
(TIF)
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S11 Fig. Frequency of the APOE gene alleles with age in GERA. Frequency of the ε2 (A), ε3
(B), and ε4 (C) alleles across GERA age bins. Data points are frequencies within 5-year interval
age bins (± 2 SE), with the center of the bin indicated on the x-axis (except for the first and the
last bins). Bins with ages below 38 years are merged into 1 bin because of the relatively small
sample sizes per bin. The dashed line shows the expected frequency based on the null model,
accounting for confounding batch effects and changes in ancestry. See S1 Data for underlying
data.
(TIF)
S12 Fig. Enrollments of individuals in the Kaiser Permanente Medical Care Plan. (A) Years
enrolled in the care plan at the time of the survey (mean ± SD) per age bin. The x-axis indicates
the center of 5-year interval age bins (except the last category). (B) Years enrolled in the plan
(mean ± SD) for individuals >70 years old versus the rs6857 (APOE) genotype that they carry.
See S1 Data for underlying data.
(TIF)
S13 Fig. Testing for the influence of single genetic variants on age-specific mortality in the
GERA cohort. Manhattan plot of P values testing for a change in allele frequency with age
using the version of the model with age treated as an ordinal variable. The plot only includes
the filtered genotyped SNPs in the GERA study. Red line marks the P = 5 × 10−8 threshold.
The signal for variant on chromosome 18 is presumably caused by genotyping error, as other
closely linked variants did not show a similar behavior, and the signal was lost when the variant
was imputed using a leave-one-out approach. See S1 Data for underlying data.
(TIF)
S14 Fig. Quantile-quantile plots for model results for individual variants in the UK Bio-
bank. Quantile-quantile plots for significant change in allele frequency with father’s (A) and
mother’s (B) age at death. The red lines indicate distribution of the P values under the null (no
change in frequency) and the shaded bands represent the 95% confidence intervals, assuming
independent SNPs. See S2 Data for underlying data.
(TIF)
S15 Fig. Effect of rs1051730 (CHRNA3) on survival in GERA (P~8.6 × 10−3). Allele fre-
quency trajectory of rs1051730 with age for males and females together (A) and separately (B).
The data points are the frequencies within 10-year interval age bins (± 2 SE). The x-axis indi-
cates the center of the age bin (except for the first and the last bins). The dashed line shows the
expected frequency based on the null model, accounting for confounding batch effects and
changes in ancestry. See S1 Data for underlying data.
(TIF)
S16 Fig. Allele frequencies of variants in the MEOX2 locus with mother’s age at death in
the UK Biobank. Plots are for 4 genotyped SNPs in moderate linkage disequilibrium with
P< 10−4 for the change in allele frequency with mother’s age at death. Data points are frequen-
cies within 5-year interval age bins (± 2 SE), with the center of the bin indicated on the x-axis
(except for the first and the last bins). The dashed line shows the expected frequency based on
the null model, accounting for confounding batch effects and changes in ancestry. See S2 Data
for underlying data.
(TIF)
S17 Fig. No significant effect of rs4721453 (near MEOX2) on survival in GERA (P~0.023).
Allele frequency trajectory of rs4721453 with age for males and females together (A) and sepa-
rately (B). The data points are the frequencies within 10-year interval age bins (± 2 SE). The x-
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axis indicates the center of the age bin (except for the first and the last bins). The dashed line
shows the expected frequency based on the null model, accounting for confounding batch
effects and changes in ancestry. See S1 Data for underlying data.
(TIF)
S18 Fig. Ascertainment bias towards older participants introduced by using parental ages
at death in the UK Biobank. Fraction of the participants in each age bin (bin size of 3 years)
who reported their father’s or mother’s age at death. See S2 Data for underlying data.
(TIF)
S19 Fig. Testing for a significant age by sex effect of individual genetic variants in the UK
Biobank. (A) Manhattan plot of P values, testing a difference between fathers and mothers in
the change in allele frequency with parental age at death. (B) Allele frequencies as a function of
father’s and mother’s age at death for top SNPs with age effects: rs4721453 (near MEOX2),
rs11858836 (near CHRNA3), and rs769449 (APOE). The data points are the frequencies within
5-year interval age bins (± 2 SE). The x-axis indicates the center of the age bin (except for the
first and the last bins). The dashed line shows the expected frequency based on the null model,
accounting for confounding batch effects and changes in ancestry. See S2 Data for underlying
data.
(TIF)
S20 Fig. Heat map showing interdependence between the age effects of pairs of trait-asso-
ciated variants in the UK Biobank. Each square [i,j] shows the effect size (log[hazard ratio])
of the polygenic score for trait i on father’s (left) or mother’s (right) survival in the Cox model,
after accounting for the effect of the polygenic score of trait j (i.e., incorporating the polygenic
score for trait j as a covariate in the null model, see Materials and methods). Squares on the
diagonal (marked by black rectangles) show the effect size of the polygenic score without
accounting for the score for other traits. See S2 Data for underlying data.
(TIF)
S21 Fig. Testing for age effect of sets of trait-associated variants in the UK Biobank, treat-
ing age variables as ordinal. Quantile-quantile plots for changes in polygenic score of 42 traits
(see S1 Table) with father’s (A) or mother’s (B) age at death, after accounting for confounding
batch effects, changes in ancestry, and the participant’s age, sex, year of birth, and the Town-
send index (a measure of socioeconomic status). The red lines indicate the distribution of the
P values under the null model. Signs “+” and “−” indicate protective and deleterious effects
associated with higher values of polygenic scores, respectively. See S2 Data for underlying data.
(TIF)
S22 Fig. Testing for age by sex effect of sets of trait-associated variants in the UK Biobank.
(A) Quantile-quantile plot for changes in polygenic score of 42 traits (see S1 Table) with paren-
tal ages at death that are different between fathers and mothers of the UK Biobank participants.
The red lines indicate the distribution of the P values under the null. (B) The trend in poly-
genic score with parental ages at death for total cholesterol and coronary artery disease, which
show significant age by sex effects. The data points are the mean polygenic scores within
5-year interval age bins (± 2 SE). The x-axis indicates the center of the age bin (except for the
first and the last bins). The dashed line shows the expected polygenic score based on the null
model, accounting for confounding batch effects, changes in ancestry, and the participant’s
age, sex, year of birth, and the Townsend index (a measure of socioeconomic status). See S2
Data for underlying data.
(TIF)
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S23 Fig. Trajectories of polygenic scores with father’s age for traits associated with pater-
nal survival in the UK Biobank. Each plot shows (in blue) the mean polygenic score (± 2 SE)
among the fathers who died in a 5-year interval centered around the plotted discs, and (in
black) the mean polygenic score among fathers alive up to a given age, i.e., all fathers with age
or age at death (if deceased) exceeding a given age. The dashed lines show the expected
changes in polygenic scores based on the null model. If there is no effect of the score on sur-
vival at a given time (age), then the score among those who died (blue disc) should be the same
as the score among those who were alive at the previous time interval. Thus, the divergence
between the blue and the black lines in any time interval is an indicator of the effect of the
score on survival (and its direction) within that interval. The precise effect, however, also
depends on the total hazard rate of the sample, which varies by age. See S2 Data for underlying
data.
(TIF)
S24 Fig. Trajectories of polygenic scores with mother’s age for traits associated with mater-
nal survival in the UK Biobank. Same as S23 Fig, but plotted for mothers (with red instead of
blue). See S2 Data for underlying data.
(TIF)
S25 Fig. Protective effect of later predicted puberty timing on survival in GERA
(P~6.7 × 10−3). Polygenic score for puberty timing with age of the participants. The data
points are the mean scores within 10-year interval age bins (± 2 SE). The x-axis indicates the
center of the age bin (except for the first and the last bins). The dashed line shows the expected
score based on the null model, accounting for confounding batch effects and changes in ances-
try. See S1 Data for underlying data.
(TIF)
S26 Fig. Testing for stabilizing selection on traits in the UK Biobank. Quantile-quantile
plots testing for a change in the squared difference of polygenic score from the mean with
fathers’ (A) and mothers’ (B) age at death, treating age variables as ordinal. 42 traits were tested
(see S1 Table). The red line indicates the distribution of the P values under the null model. See
S2 Data for underlying data.
(TIF)
S27 Fig. Power of the model to detect changes in allele frequency with age. Same as Fig 1,
but with 500,000 samples evenly distributed among age categories and only showing the results
using models with age treated as a categorical variable. As can be seen, there should be sub-
stantial power to detect such effects even for relatively rare variants (i.e., at a couple of percent
frequency in the population).
(TIF)
S28 Fig. Association between variants influencing age at first birth and apparent fertility
in the UK Biobank (P~4.2 × 10−8). Polygenic score versus the number of siblings for 112,130
participants with mother’s age 50 years. Data points are mean scores (± 2 SE). The polygenic
score was regressed on the number of siblings, accounting for the confounding batch effects,
changes in ancestry, and the participant’s age, sex, year of birth, and the Townsend index (a
measure of socioeconomic status). The dashed line shows the expected score based on the null
model. See S2 Data for underlying data.
(TIF)
S29 Fig. Ascertainment bias towards older participants for older parental age at death cat-
egories in the UK Biobank. Fraction of the participants > 61 years old (last 3 age categories in
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S18 Fig) in each parental age bin. Assuming parents of older participants on average belong to
earlier generations, older age at death categories will contain parents born earlier. See S2 Data
for underlying data.
(TIF)
S1 Table. List of phenotypes and abbreviations. The numbers of loci passing quality control
measures are shown for each data set.
(DOCX)
S2 Table. Results of the Cox model for association of polygenic scores for 42 traits with
survival of parents of the UK Biobank participants.
(XLSX)
S3 Table. Age dependency of hazard ratios for the top associations with parental survival
in the UK Biobank under the Cox model.
(DOCX)
S4 Table. Replication of associations in the discovery panel (UK Biobank individuals of
British ancestry) in the UK Biobank participants of non-British ancestry.
(DOCX)
S5 Table. Testing for change in polygenic scores with age of the GERA participants.
(DOCX)
S1 Data. Numerical values underlying the main and supplemental figures presenting anal-
yses on the GERA data set. For genome-wide analyses, data for SNPs with P< 10−5 are
shown.
(XLSX)
S2 Data. Numerical values underlying the main and supplemental figures presenting anal-
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